Blog
RSS FeedPosted by Michael Wonder on 20 Dec 2024
ICER publishes fourth annual assessment of barriers to fair access within US commercial insurance prescription drug coverage
19 December 2024 - Most payers evaluated offer fair access across the domains reviewed; findings underscore the need for greater ...
Posted by Michael Wonder on 12 Dec 2024
ICER announces most significant drug price hikes unsupported by new clinical evidence in US
12 December 2024 - Of 10 high expenditure drugs that had substantial 2023 net price increases, five were not supported ...
Posted by Michael Wonder on 10 Dec 2024
ICER releases draft evidence report on treatment for acute pain
9 December 2024 - Public comment period now open until 13 January 2025; requests to make oral comment during public ...
Posted by Michael Wonder on 28 Nov 2024
ICER to assess treatment for secondary progressive multiple sclerosis
19 November 2024 - Report will be subject of CTAF meeting in June 2025; draft scoping document open to public ...
Posted by Michael Wonder on 18 Sep 2024
The ICER developing special report for submission to CMS as part of public comment process on Medicare drug price negotiations
18 September 2024 - Report to reflect legislative specifications in the Inflation Reduction Act and subsequent CMS guidance regarding price ...
Posted by Michael Wonder on 06 Sep 2024
ICER publishes evidence report on treatments for transthyretin amyloid cardiomyopathy
5 September 2024 - Current evidence suggests that tafamidis and acoramidis provide a net health benefit when compared to no ...
Posted by Michael Wonder on 22 Aug 2024
ICER publishes final evidence report on treatment for anaemia in myelodysplastic syndrome
22 August 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate net health benefits for ...
Posted by Michael Wonder on 30 Jul 2024
ICER to assess treatment for acute pain
29 July 2024 - Report will be subject of Midwest CEPAC meeting in February 2025; draft scoping document open to ...
Posted by Michael Wonder on 17 Jul 2024
ICER releases draft evidence report on treatments for transthyretin amyloid cardiomyopathy
17 July 2024 - Public comment period now open until 13 August 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 16 Jul 2024
ICER publishes final evidence report on treatment for chronic obstructive pulmonary disease
16 July 2024 - Independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for ...
Posted by Michael Wonder on 02 Jul 2024
ICER publishes evidence report on treatment for anaemia in myelodysplastic syndrome
2 July 2024 - There are significant uncertainties regarding long term efficacy and safety of imetelstat; treatment would achieve common ...
Posted by Michael Wonder on 27 Jun 2024
ICER publishes final evidence report on treatment for post-traumatic stress disorder
27 June 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits ...
Posted by Michael Wonder on 20 Jun 2024
The value of the quality adjusted life years
19 June 2024 - Concerns about quality-adjusted life years (QALYs) being discriminatory have reached a fever pitch in the US, culminating ...
Posted by Michael Wonder on 20 Jun 2024
What good are whizzy new drugs if the world can’t afford them?
14 June 2024 - Bringing gene therapies and obesity drugs to the masses will require financial innovation too, says Steven Pearson. ...
Posted by Michael Wonder on 05 Jun 2024
ICER publishes protocol for annual assessment of drug coverage policies that present barriers to fair access
5 June 2024 - This year’s analysis will include the top ten commercial formularies by covered lives, and include drugs ...